Cardiovascular risk in pediatric nonalcoholic fatty liver disease: Recent advances

Clinical Lipidology

Volumn 10, Issue 4, 2015, Pages 351-362

  Baskar, Shankar ^a   Jhaveri, Simone ^a   Alkhouri, Naim ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cardiovascular diseases; dyslipidemias; fatty liver; genetic; inflammation; insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; oxidative stress; pediatric obesity; polymorphism

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; HEPATOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BLOOD CLOTTING DISORDER; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD OBESITY; DISEASE ASSOCIATION; FLOW MEDIATED DILATION; FUNCTIONAL ANATOMY; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID COMPOSITION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEDIATRICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASODILATATION;

EID: 84939806038     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.15.26     Document Type: Review

References (75)

1. Nobili V, Alkhouri N, Alisi A et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr. 169(2), 170-176 (2015).
2. Vajro P, Lenta S, Socha P et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J. Pediatr. Gastroenterol. Nutr. 54(5), 700-713 (2012).
3. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118(4), 1388-1393 (2006).
4. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58(11), 1538-1544 (2009).
5. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118(3), 277-283 (2008).
6. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999-2012. JAMA Pediatr. 168(6), 561-566 (2014).
7. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311(8), 806-814 (2014).
8. Kelly AS, Barlow SE, Rao G et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. Circulation 128(15), 1689-1712 (2013).
9. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47(3), 181-190 (2015).
10. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch. Pediatr. Adolesc. Med. 157(8), 821-827 (2003).
11. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110(16), 2494-2497 (2004).
12. Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab. Syndr. Relat. Disord. 11(2), 71-80 (2013).
13. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350(23), 2362-2374 (2004).
14. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J. Pediatr. Gastroenterol. Nutr. 43(4), 413-427 (2006).
15. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 115(5), e561-e565 (2005).
16. Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int. J. Obes. (Lond.) 32(2), 381-387 (2008).
17. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363(14), 1341-1350 (2010).
18. Wong VW, Wong GL, Yip GW et al. Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 60(12), 1721-1727 (2011).
19. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 20(7), 1724-1745 (2014).
20. Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among Type 2 diabetic patients. Diabetes Care 30(5), 1212-1218 (2007).
21. Linder K, Springer F, Machann J et al. Relationships of body composition and liver fat content with insulin resistance in obesity-matched adolescents and adults. Obesity (Silver Spring) 22(5), 1325-1331 (2014).
22. McGill HC Jr, McMahan CA, Herderick EE et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler. Thromb. Vasc. Biol. 20(3), 836-845 (2000).
23. Berenson GS, Wattigney WA, Tracy RE et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am. J. Cardiol. 70(9), 851-858 (1992).
24. Lawlor DA, Callaway M, Macdonald-Wallis C et al. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J. Clin. Endocrinol. Metab. 99(3), e410-e417 (2014).
25. Pacifico L, Cantisani V, Ricci P et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr. Res. 63(4), 423-427 (2008).
26. Caserta CA, Pendino GM, Amante A et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am. J. Epidemiol. 171(11), 1195-1202 (2010).
27. Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis 209(2), 463-468 (2010).
28. Nobili V, Alkhouri N, Bartuli A et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr. Res. 67(6), 665-670 (2010).
29. Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 204(2), 538-543 (2009).
30. Pacifico L, Bonci E, Andreoli G et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr. Metab. Cardiovasc. Dis. 24(7), 737-743 (2014).
31. Pacifico L, Anania C, Martino F et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 52(5), 1643-1651 (2010).
32. Weghuber D, Roden M, Franz C et al. Vascular function in obese children with non-alcoholic fatty liver disease. Int. J. Pediatr. Obes. 6(2), 120-127 (2011).
33. de Groot E, Hovingh GK, Wiegman A et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109(23 Suppl. 1), III33-III38 (2004).
34. Demircioglu F, Kocyigit A, Arslan N, Cakmakci H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 47(1), 68-75 (2008).
35. Gokce S, Atbinici Z, Aycan Z, Cinar HG, Zorlu P. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatr. Cardiol. 34(2), 308-315 (2013).
36. Alp H, Karaarslan S, Selver Eklioglu B, Atabek ME, Altin H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can. J. Cardiol. 29(9), 1118-1125 (2013).
37. Akin L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmali F, Mazicioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr. 102(3), e107-e113 (2013).
38. Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease. J. Pediatr. Endocrinol. Metab. 25(9-10), 927-934 (2012).
39. Sert A, Pirgon O, Aypar E, Yilmaz H, Dundar B. Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. J. Clin. Res. Pediatr. Endocrinol. 5(3), 182-188 (2013).
40. Mattace-Raso FU, van der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113(5), 657-663 (2006).
41. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. Heart J. 27(21), 2588-2605 (2006).
42. Huang RC, Beilin LJ, Ayonrinde O et al. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology 58(4), 1306-1314 (2013).
43. Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26(5), 1235-1241 (1995).
44. Petta S, Argano C, Colomba D et al. Epicardial fat, cardiac geometry and cardiac function in patients with nonalcoholic fatty liver disease: association with the severity of liver disease. J. Hepatol. 62(4), 928-933 (2014).
45. Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am. J. Cardiol. 112(3), 436-443 (2013).
46. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J. Am. Heart Assoc. 3(2), e000582 (2014).
47. Fintini D, Chinali M, Cafiero G et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr. Metab. Cardiovasc. Dis. 24(1), 72-74 (2014).
48. Singh GK, Vitola BE, Holland MR et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 162(6), 1160-8, 1168.e1 (2013).
49. Pacifico L, Di Martino M, De Merulis A et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59(2), 461-470 (2014).
50. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51(4), 1209-1217 (2010).
51. Petta S, Valenti L, Marchesini G et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with nonalcoholic fatty liver disease. PLoS One 8(9), e74089 (2013).
52. Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32(4), 887-893 (2012).
53. Pare G, Ridker PM, Rose L et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet. 7(4), e1001374 (2011).
54. Kozlitina J, Smagris E, Stender S et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46(4), 352-356 (2014).
55. Liu YL, Reeves HL, Burt AD et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with nonalcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).
56. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell. Metab. 14(5), 575-585 (2011).
57. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr. Rev. 27(3), 242-259 (2006).
58. Rask-Madsen C, Li Q, Freund B et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell. Metab. 11(5), 379-389 (2010).
59. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 116(7), 1793-1801 (2006).
60. Yoneda M, Mawatari H, Fujita K et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42(7), 573-582 (2007).
61. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig. Dis. Sci. 55(9), 2644-2650 (2010).
62. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 239(1), 192-202 (2015).
63. Griffin JL, Wang X, Stanley E. Does our gut microbiome predict cardiovascular risk A review of the evidence from metabolomics. Circ. Cardiovasc. Genet. 8(1), 187-191 (2015).
64. Nicholson JK, Holmes E, Kinross J et al. Host-gut microbiota metabolic interactions. Science 336(6086), 1262-1267 (2012).
65. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91(9), 2488-2496 (1995).
66. Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin. Thromb. Hemost. 39(2), 214-228 (2013).
67. Verrijken A, Francque S, Mertens I et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 59(1), 121-129 (2014).
68. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112(1), 91-100 (2003).
69. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH. TNF-alpha or adiponectin Hepatology 40(1), 46-54 (2004).
70. Huang XD, Fan Y, Zhang H et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J. Gastroenterol. 14(18), 2888-2893 (2008).
71. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14), 1730-1737 (2004).
72. Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104(25), 3052-3056 (2001).
73. Vassilopoulos D, Lazaros G, Tsioufis C, Vasileiou P, Stefanadis C, Pectasides D. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int. J. Cardiol. 160(1), 66-68 (2012).
74. Rittig K, Thamer C, Haupt A et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 207(2), 341-342 (2009).
75. Nascimbeni F, Pais R, Bellentani S et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 59(4), 859-871 (2013).